Swimmer’s plot for all evaluable patients treated with ruxolitinib. Each bar represents 1 subject in the study. Right arrow cap indicates ongoing treatment. ALCL included systemic ALK⁻ ALCL (n = 3) and primary cutaneous ALCL (n = 1). G/D TCL included hepatosplenic T-cell lymphoma (n = 2), monomorphic epitheliotropic intestinal T-cell lymphoma (n = 1), and primary cutaneous γδ-TCL (n = 1). JAK/STAT Mutations: only JAK or STAT mutations listed. (−) indicates no JAK or STAT mutation present. Additional mutations identified by next generation sequencing (NGS) are provided in supplemental Table 1. pSTAT3: (+) is defined as ≥30% expression in tumor cells by immunohistochemical staining; (−) defined as <30% expression. ND indicates that NGS or IHC for pSTAT3 was not done. Cohorts: cohort 1 (JAK/STAT mutations present); cohort 2 (pSTAT3 ≥30% by IHC); cohort 3 (neither or ND). AITL/TFH, angioimmunoblastic T-cell lymphoma and other T-follicular helper lymphomas; ALK⁻ ALCL, ALK⁻ anaplastic large cell lymphoma; BOR, best overall response; POD, progression of disease.